GAITHERSBURG, Md., March 05, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced it will report its fourth quarter 2019 financial and operating results following the close of U.S. financial markets on Wednesday, March 11, 2020.
About NovavaxNovavax, Inc. (Nasdaq:NVAX), is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, is currently in a pivotal Phase 3 clinical trial to address key factors that can lead to the poor effectiveness of currently approved flu vaccines. ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine to demonstrate efficacy in a Phase 3 clinical trial. Novavax recently initiated development of a vaccine program against COVID-19. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce a new class of highly immunogenic nanoparticles addressing urgent global health needs.For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.Investors
Erika Trahan
ir@novavax.com
240-268-2022Westwicke
John Woolford
john.woolford@westwicke.com
443-213-0506Media
Amy Speak
amy@speaklifescience.com
617-420-2461
Bay Street News